{
}
Roche's Phase IIb PADOVA study of prasinezumab in early-stage Parkinson's disease did not meet its primary endpoint of time to confirmed motor progression, though it showed promising trends in secondary endpoints, particularly in patients also treated with levodopa. The drug was well tolerated with no new safety concerns reported. Roche plans to present full results at an upcoming medical meeting, emphasizing the need for further exploration in the absence of disease-modifying treatments for Parkinson's.
Roche's Parkinson's drug, prasinezumab, has failed a Phase IIb trial, despite showing potential clinical efficacy in delaying motor progression. While the results indicated positive trends in secondary endpoints, they lacked statistical significance, prompting analysts to call the data "promising but leaves uncertainty." Roche plans to continue related studies and may consider a new trial to further explore the findings.
Roche and Prothena's Parkinson's antibody treatment, prasinezumab, failed to meet its primary endpoint in the phase 2b PADOVA study, although it showed a 16% delay in motor progression compared to placebo. The drug was well tolerated, and Roche plans to further evaluate the data and collaborate with health authorities on next steps. Parkinson's disease remains difficult to treat, with many therapies struggling to progress through clinical trials.
Roche's experimental Parkinson's drug, prasinezumab, failed to meet its primary goal in a mid-stage trial, not significantly delaying motor symptom progression in early-stage patients. Despite this setback, the drug showed potential clinical efficacy and positive trends in other trial objectives. Roche plans to further evaluate the data and collaborate with health authorities on next steps.
Roche has received approval from the European Medicines Agency for Vabysmo, a 6.0 mg single-dose prefilled syringe, to treat neovascular age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. This treatment addresses the needs of over nine million people in the EU, offering a more convenient administration method for ophthalmologists and potentially reducing the treatment burden for patients.
Roche has received EU approval for its Vabysmo prefilled syringe, targeting three retinal conditions that lead to blindness: wet age-related macular degeneration, diabetic macular oedema, and macular oedema following retinal vein occlusion. This ready-to-use formulation complements the existing vial option and aims to challenge Regeneron's Eylea, which currently dominates the market. With Vabysmo's sales surging 324% to $2.64bn, forecasts suggest it could reach $8.78bn by 2030, while Eylea's sales are expected to decline significantly.
Roche plans to acquire Poseida Therapeutics for $1.5 billion, focusing on allogeneic CAR-T cell therapies, including the investigational dual CAR-T therapy P-CD19CD20-ALLO1, currently in phase 1 trials for B-cell malignancies. The acquisition aims to enhance development in oncology, immunology, and neurology, with potential applications for multiple sclerosis and systemic lupus erythematosus. The deal is expected to close in Q1 2025.
Levi Garraway
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Roche's prasinezumab shows mixed results in Parkinson's disease study
16:53 19.12.2024
Roche's Parkinson's drug prasinezumab fails to achieve significant trial results
15:54 19.12.2024
roche and prothena's parkinsons antibody treatment fails in phase 2 trial
United States Dollar
UCB SA
Hoffmann-La Roche AG
Prothena Corp PLC
Novartis AG
BIOGEN
IRL
Levi Garraway
Show more
15:39 19.12.2024
Roche's Parkinson's drug fails to meet primary trial objectives
14:44 19.12.2024
Roche receives EU approval for Vabysmo to treat major retinal conditions
13:00 14.12.2024
Roche gains EU approval for Vabysmo prefilled syringe to challenge Eylea
13:19 13.12.2024
roche to acquire poseida for car t cell therapy development
22:08 09.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Government Economic Policies
Workplace Trends
Industry Mergers & Acquisitions
Stock Market Updates
Fintech Startups
Venture Capital Investments
Financial Scams and Security
Finance Mergers & Acquisitions
CEO Changes
Cryptocurrency Trends
Emerging Startups
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: